ArQule to Present at Jefferies Global Healthcare Conference

  ArQule to Present at Jefferies Global Healthcare Conference

Jefferies 2014 Global Healthcare Conference

Business Wire

WOBURN, Mass. -- May 29, 2014

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at
the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at
10:30 a.m. The presentation will be web cast and may be accessed through the
investor relations section of the Company’s website,

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase and ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s
current discovery efforts, which are based on the ArQule Kinase Inhibitor
Platform (AKIP™), are focused on the identification of novel kinase inhibitors
that are potent and selective against their targets.


ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
Press spacebar to pause and continue. Press esc to stop.